Highlights of weekly biotech stock moves

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) was off $0.23 to $18.69 last week after beginning submission of a rolling NDA to FDA for ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company, which requested Priority Review, is seeking accelerated approval based largely on data from the pivotal Phase II PACE trial.

Ariad plans to complete the submission this quarter and expects a decision in 1Q13. The company also plans to submit an MAA to EMA this quarter...